← Back to patent-cliff list
MTL-CEBPA
Tier C — Watch / tradeMTL-CEBPA
University of Texas Southwestern Medical Center
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：CEBPA
Indications (approved)：Hepatitis C, Hepatocellular carcinoma, Hepatitis B, Solid tumour, Liver cancer
Regional status
US
Phase II
2022-01-01
EU
Phase I
2016-03-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of MTL-CEBPA?
Approved indications include: Hepatitis C, Hepatocellular carcinoma, Hepatitis B, Solid tumour, Liver cancer.
When does the MTL-CEBPA patent expire?
No public expiry year is available for MTL-CEBPA yet; this page updates once verified.
How do I get a quote for MTL-CEBPA intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21